NGM लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

खरीदें 116449 min ago

@ $1.435

जारी किया गया: 15 Feb 2024 @ 02:01

वापसी: 7.32%

पिछला सिग्नल: Feb 14 - 20:22

पिछला सिग्नल: बेचें

वापसी: -3.68 %

Live Chart Being Loaded With Signals

Commentary (5 Apr 2024 @ 01:30):

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...

Stats
आज की मात्रा	0.00
औसत मात्रा	969 866
बाजार मूल्य	128.53M
EPS	$-0.330 ( 2024-05-02 )
अगली कमाई की तारीख	( $0 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.890
ATR14	$0.00400 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Tcg Opportunity Iii Gp, Llc	Buy	1 000	Common Stock
2024-04-05	Tcg Opportunity Iii Gp, Llc	Sell	44 000	Common Stock
2024-04-05	Column Group Gp, Lp	Buy	1 000	Common Stock
2024-04-05	Column Group Gp, Lp	Sell	44 000	Common Stock
2024-04-05	Column Group L P	Buy	1 000	Common Stock

INSIDER POWER
-56.40
Last 100 transactions
Buy: 3 241 050 \| Sell: 9 885 031

मात्रा सहसंबंध

लंबा: -0.36 (neutral)

छोटा: 0.00 (neutral)

Signal:(48.109) Neutral

NGM Biopharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
NVCN	0.959
TIOAU	0.946
AVEO	0.945
NTNX	0.944
ADTH	0.943
BNIXU	0.94
MSDA	0.939
ROVR	0.939
BUFF	0.938
NFLX	0.938

10 सबसे अधिक नकारात्मक सहसंबंध
AGFY	-0.958
ENNV	-0.956
IRBT	-0.954
KBNT	-0.948
CSSEP	-0.947
FWRD	-0.944
BIOL	-0.942
TCFC	-0.94
TBLT	-0.94
GOVX	-0.94

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

NGM Biopharmaceuticals सहसंबंध - मुद्रा/वस्त्र

-0.73
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

0.47
( neutral )

NGM Biopharmaceuticals वित्तीय

Annual	2023
राजस्व:	$4.42M
सकल लाभ:	$2.20M (49.72 %)
EPS:	$-1.730

FY	2023
राजस्व:	$4.42M
सकल लाभ:	$2.20M (49.72 %)
EPS:	$-1.730

FY	2022
राजस्व:	$55.33M
सकल लाभ:	$49.35M (89.19 %)
EPS:	$-1.990

FY	2021
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-1.555

Financial Reports:

No articles found.

NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.